Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jul 28:10:20.
doi: 10.1186/1471-2369-10-20.

Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

Katherine A Barraclough  1 , Euan Noble, Diana Leary, Fiona Brown, Carmel M Hawley, Scott B Campbell, Nicole M Isbel, David W Mudge, Carolyn L van Eps, Joanna M Sturtevant, David W Johnson
Affiliations
Randomized Controlled Trial

Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

Katherine A Barraclough et al. BMC Nephrol. .

Abstract

Background: The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin ES) administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated peritoneal dialysis (PD) patients than conventional oral iron supplementation (Ferrogradumet).

Methods: Inclusion criteria are peritoneal dialysis patients treated with darbepoietin alpha (DPO; Aranesp(R), Amgen) for >or= 1 month. Patients will be randomized 1:1 to receive either slow-release ferrous sulphate (1 tablet twice daily; control) or HIP (1 tablet twice daily) for a period of 6 months. The study will follow an open-label design but outcome assessors will be blinded to study treatment. During the 6-month study period, haemoglobin levels will be measured monthly and iron studies (including transferring saturation [TSAT] measurements) will be performed bi-monthly. The primary outcome measure will be the difference in TSAT levels between the 2 groups at the end of the 6 month study period, adjusted for baseline values using analysis of covariance (ANCOVA). Secondary outcome measures will include serum ferritin concentration, haemoglobin level, DPO dosage, Key's index (DPO dosage divided by haemoglobin concentration), and occurrence of adverse events (especially gastrointestinal adverse events).

Discussion: This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their peritoneal dialysis patients determine whether HIP administration more effectively augments iron stores in ESP-treated PD patients than conventional oral iron supplementation.

Trial registration: Australia New Zealand Clinical Trials Registry number ACTRN12609000432213.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial schema.
Figure 2
Figure 2
Trial schedule (all tests are ordered as per routine clinical practice).
See this image and copyright information in PMC

References

    1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD) Kidney Int. 1985;28:1–5. doi: 10.1038/ki.1985.109. - DOI - PubMed
    1. Eschbach JW Jr, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med. 1967;276:653–658. - PubMed
    1. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int. 1996;50:1373–1391. doi: 10.1038/ki.1996.452. - DOI - PubMed
    1. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study) Am J Kidney Dis. 1999;34:1089–1095. doi: 10.1016/S0272-6386(99)70015-6. - DOI - PubMed
    1. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. 1999;55(Suppl 69):S61–6. doi: 10.1046/j.1523-1755.1999.055Suppl.69061.x. - DOI - PubMed

Publication types

MeSH terms